Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications

Abstract: Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cardinali, Daniel Pedro, Cano Barquilla, Pilar, Jiménez Ortega, Vanesa, Esquifino, Ana I.
Formato: Artículo
Lenguaje:Inglés
Inglés
Publicado: Karger Publishers 2019
Materias:
MELATONINA
RITMO CIRCADIANO
SINDROME METABOLICO
AGONISTAS
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/1619
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139123456789-1619
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
Inglés
topic MELATONINA
RITMO CIRCADIANO
SINDROME METABOLICO
AGONISTAS
spellingShingle MELATONINA
RITMO CIRCADIANO
SINDROME METABOLICO
AGONISTAS
Cardinali, Daniel Pedro
Cano Barquilla, Pilar
Jiménez Ortega, Vanesa
Esquifino, Ana I.
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
topic_facet MELATONINA
RITMO CIRCADIANO
SINDROME METABOLICO
AGONISTAS
description Abstract: Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep‐wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequela in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbilities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease merits further investigation.
format Artículo
author Cardinali, Daniel Pedro
Cano Barquilla, Pilar
Jiménez Ortega, Vanesa
Esquifino, Ana I.
author_facet Cardinali, Daniel Pedro
Cano Barquilla, Pilar
Jiménez Ortega, Vanesa
Esquifino, Ana I.
author_sort Cardinali, Daniel Pedro
title Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title_short Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title_full Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title_fullStr Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title_full_unstemmed Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
title_sort melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
publisher Karger Publishers
publishDate 2019
url https://repositorio.uca.edu.ar/handle/123456789/1619
work_keys_str_mv AT cardinalidanielpedro melatoninandthemetabolicsyndromephysiopathologicandtherapeuticalimplications
AT canobarquillapilar melatoninandthemetabolicsyndromephysiopathologicandtherapeuticalimplications
AT jimenezortegavanesa melatoninandthemetabolicsyndromephysiopathologicandtherapeuticalimplications
AT esquifinoanai melatoninandthemetabolicsyndromephysiopathologicandtherapeuticalimplications
bdutipo_str Repositorios
_version_ 1764820525726564354

Ejemplares similares